In conclusion, our study demonstrated that APM signature score and APM signature-based risk score could be potential markers in predicting survival outcome, IDH status, 1p19q status, MGMT status, and molecular subtypes of glioma patients. This evidence concerns the gene IDH1 and central nervous system cancer.